Biofilms occur in natural aquatic ecosystems and on surfaces of biomaterial
s. They are generally associated with clinical infections predominantly of
prothetic hip joints, heart valves and catheters.
Sessile microorganisms may be intimately associated with each other and to
solid substratum through binding to and inclusion into exopolymer matrices
an biofilms. The establishment of functional colonies within the exopolymer
ic matrices generate physico-chemical gradients within biofilms, that modif
y the metabolism and cell-wall properties of the microorganism. A consequen
ce of biofilm growth is enhanced microbial resistance to chemical antimicro
bial agents and antibiotics. Investigations on the antimicrobial efficacy o
f antibiotics, antiseptics and antimicrobial heavy ions, however, gave cont
roversial results. No single antimicrobial substance has been developed for
the efficient eradication of adherent bacteria.
This review elucidates the mechanisms of microbial resistance in biofilms a
nd strategies for the prevention of biofilm development. Pharmacokinetical
and pharmacodynamical issues for the screening of biofilm-active drugs are
presented. Combinations of antistaphylococcal antibiotics with rifampin may
be advantageous for preventing and curing biomaterial infections.